Clinical trials: Sepsis
Sepsis, Severe
Recombinant Interleukin-7 (CYT107) to Restore Absolute Lymphocyte Counts in Sepsis Patients
This phase II randomized study will assess the effect of receiving IV recombinant human IL-7 (CYT107) versus placebo in lymphopenic sepsis patients The aim is to confirm the immune cell reconstitution observed in other studies…
- Trial name
- IRIS-7-C&D (NCT03821038)
- Testing
- CYT107
- Where
- 10 sites in United States, France
- Volunteers
- 21 people
- Sponsor
- Revimmune
Pulmonary Embolism, Medical Device Complication
Angel® Catheter Post Market Registry
This is a post-market, observational, retrospective multi-center Registry designed to gather information on the performance of the Angel® Catheter in general clinical practice.
- Conditions
- Pulmonary Embolism, Medical Device Complication, Deep Vein Thrombosis, Catheter Thrombosis
- Trial name
- NCT02917135
- Testing
- Angel® Catheter
- Where
- 5 sites in Germany, Italy and 1 more
- Volunteers
- 2,000 people
- Sponsor
- BiO2 Medical
Oropharyngeal Candidiasis, Candidemia
Study of Mycamine® in Children With Fungal Infections to Evaluate Safety and Blood Levels of the Drug
Children with fungal infections will be divided into two groups by weight. Children weighing < 25 kg will receive a higher dose of study medication (per kg body weight) for 10 to 14 days than children weighing > 25 kg.
- Conditions
- Oropharyngeal Candidiasis, Candidemia, Invasive Candidiasis, Esophageal Candidiasis
- Trial name
- NCT00608335
- Testing
- Micafungin
- Where
- 13 sites in United States, South Africa
- Volunteers
- 84 people
- Sponsor
- Astellas Pharma Inc
Bloodstream Infection, Sepsis
Clinical Performance Study of Microbio InfectID-BSI for Detection of Bacteria and Yeast With Patient Blood Samples
The objective of the study is to determine the efficacy of the Microbio InfectID-BSI qPCR kit in a clinical laboratory environment using patient whole blood for pathogen detection and identification versus standard of care…
- Conditions
- Bloodstream Infection, Sepsis, Septic Shock
- Trial name
- IID-BSIqPCR (NCT06531031)
- Testing
- InfectID-BSI (Bloodstream Infection) qPCR Assay
- Where
- 8 sites in United States, Australia and 1 more
- Volunteers
- 1,500 people
- Sponsor
- Microbio Co Ltd
Drug Safety
Clinical Assessment of Safety and Tolerability of the New Monoclonal Humanized Antibody CaCP29
The novel humanized monoclonal antibody CaCP29 was developed to control the inflammatory response to various stimuli in humans and espacially during sepsis.
- Trial name
- NCT01319903
- Testing
- CaCP29, a humanized monoclonal antibody
- Where
- Germany
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- InflaRx GmbH
Invasive Candidiasis, Candidemia
Risk Of Severe Hepatic Injury In Patients With Invasive Candidiasis Treated With Echinocandins
The purpose of this study is to estimate the relative risk of severe hepatic injury in hospitalized patients with invasive candidiasis and candidemia who received anidulafungin, compared to patients who received caspofungin…
- Trial name
- NCT01213823
- Testing
- Does not apply
- Volunteers
- 536 people, healthy volunteers welcome
- Sponsor
- Pfizer
Sepsis
SEP-SEQ Trial - Determining the Etiology of Sepsis Using an Infectious Disease Diagnostic Sequencing Assay
The purpose of this study is to evaluate the performance of the Karius Infectious Diseases Plasma Sequencing Assay in patients who present to the emergency room with sepsis.
- Trial name
- NCT02730468
- Where
- United States
- Volunteers
- 350 people
- Sponsor
- Karius, Inc.
Staphylococcus Aureus Bacteremia, Staphylococcus Aureus Endocarditis
Direct Lysis of Staph Aureus Resistant Pathogen Trial of Exebacase
The purpose of this superiority study is to evaluate the efficacy and safety of exebacase in addition to standard of care antibiotics (SoCA) compared with SoCA alone for the treatment of patients with Staphylococcus aureus (S.
- Trial name
- DISRUPT (NCT04160468)
- Testing
- Exebacase
- Where
- 55 sites in United States
- Volunteers
- 259 people
- Sponsor
- ContraFect
Septic Shock
A RCT to Assess the Performance of CytoSorb for Shock Reversal in Patients With Vasoplegic Septic Shock
To assess the performance of the CytoSorb® 300 mL device for shock reversal in patients with vasoplegic septic shock.
- Trial name
- PROCYSS (NCT04963920)
- Testing
- Cytosorb® 300 ml
- Where
- 18 sites in Germany
- Volunteers
- 260 people
- Sponsor
- CytoSorbents Europe GmbH
Acute Kidney Injury, Septic Shock
Targeting Abdominal Perfusion Pressure in Septic Shock
A randomized control trial among patients with septic shock, studying the incidence, progression and recovery of AKI.
- Conditions
- Acute Kidney Injury, Septic Shock, Resuscitations
- Trial name
- MAP-APP (NCT03582046)
- Testing
- Abdominal Perfusion Pressure (APP), Mean Arterial Pressure (MAP)
- Where
- 3 sites in United States
- Volunteers
- 12 people
- Sponsor
- Potrero Medical
Infectious Diseases
A Study to Learn About the Study Medicine - Zavicefta in Patients With Sepsis or Loss of Kidney Function in Japan
The purpose of this study is to learn about the safety and how effective is Zavicefta under actual clinical practice in Japan. Zavicefta is a combination of Avibactam sodium and Ceftazidime hydrate.
- Trial name
- NCT06864585
- Testing
- Avibactam sodium/Ceftazidime hydrate
- Where
- Japan
- Volunteers
- 59 people
- Sponsor
- Pfizer
Acute Kidney Injury
Efficacy Study of a Selective Cytopheretic Device (SCD) in Patients With Acute Kidney Injury
The purpose of this protocol is to evaluate the safety of a selective cytopheretic device (SCD) in patients that are on continuous renal replacement therapy (CRRT) for acute kidney injury (AKI).
- Trial name
- NCT01400893
- Testing
- SCD
- Where
- 26 sites in United States
- Volunteers
- 134 people
- Sponsor
- SeaStar Medical
Sepsis, Acute Lung Injury
Effects of TNX-832 (Sunol cH36) in Subjects With Acute Lung Injury/Acute Respiratory Distress Syndrome
This Phase I/IIa, multi-center, randomized, placebo-controlled, single-blinded dose-escalation study evaluated TNX-832 (also referred to as ALT-836 and Sunol cH36) in subjects with suspected or proven bacteria-induced ALI/ARDS.
- Conditions
- Sepsis, Acute Lung Injury, Acute Respiratory Distress Syndrome
- Trial name
- NCT01438853
- Testing
- TNX-832
- Where
- 7 sites in United States, Canada
- Volunteers
- 18 people
- Sponsor
- Altor BioScience
Sepsis, Severe Sepsis
Plasma Inducible Nitric Oxide Synthase (iNOS) Assay and Sepsis Study
The primary objective is to demonstrate that the plasma inducible nitric oxide synthase (iNOS) assay (PliNOSa® test) has an acceptable relative risk ratio for predicting the onset of sepsis within 72 hours of testing when…
- Conditions
- Sepsis, Severe Sepsis, Septic Shock
- Trial name
- PliNOSa® Test (NCT01371929)
- Volunteers
- 166 people
- Sponsor
- Research & Diagnostic Antibodies
Necrotizing Soft Tissue Infection, Sepsis
HAT for the Treatment of Sepsis Associated With NASTI
Evaluate the impact of HAT therapy versus placebo in the treatment of patients with an acute NSTI and sepsis.
- Trial name
- NCT05157360
- Testing
- HAT
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Ascension Health
Sepsis
Single-dose/Multiple-doses Incremental Intravenous Injection of SY-005 （Recombinant Human Annexin A5）in Healthy Subjects
This is a single-dose/multiple-doses incremental, randomized, double-blind, parallel, placebo-controlled study on safety, tolerance and pharmacokinetics healthy subjects.
- Trial name
- NCT04217629
- Testing
- SY-005
- Where
- China
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- Suzhou Yabao Pharmaceutical R&D Co., Ltd.
Urinary Tract Infection Complicated, Acute Pyelonephritis
Efficacy, Safety, Tolerability of Vabomere Compared to Best Available Therapy in Treating Serious Infections in Adults
Vabomere™, (meropenem-vaborbactam) is being compared to the Best Available Therapy in the treatment of adults with selected serious infections due to Carbapenem Resistant Enterobacteriaceae
- Conditions
- Urinary Tract Infection Complicated, Acute Pyelonephritis, Hospital Acquired Bacterial Pneumonia, Ventilator-associated Bacterial Pneumonia
- Trial name
- NCT02168946
- Testing
- Vabomere, Best Available Therapy
- Where
- 50 sites in United States, Argentina and 6 more
- Volunteers
- 77 people
- Sponsor
- Rempex (a wholly owned subsidiary of Melinta Therapeutics, Inc.)
Stress Urinary Incontinence
LIBERATE International
This is a prospective, randomized, double-blind, sham-controlled clinical study. The study is designed to demonstrate that active is superior to sham for the efficacy endpoints and is deemed to have appropriate safety as compared…
- Trial name
- NCT03619174
- Testing
- Viveve Treatment
- Where
- 6 sites in Canada
- Volunteers
- 99 people
- Sponsor
- Viveve Inc.
Sepsis
Pharmacoeconomic Analysis of First Line Meropenem Versus Standard Antibiotic Treatment in Seriously Infected Secondary Nosocomial Sepsis Syndrome Patients.
This study will directly compare meropenem with standard first line antibiotic therapies in subjects entering an ICU with secondary nosocomial sepsis, or who contract sepsis while resident in an ICU.
- Trial name
- NCT00318552
- Testing
- Meropenem
- Where
- 12 sites in Hungary
- Volunteers
- 160 people
- Sponsor
- Pfizer
Acute Kidney Injury
A Safety, Tolerability, Efficacy and QoL Study of Human recAP in the Treatment of Patients With SA-AKI
The purpose of this study is to determine whether recombinant Alkaline Phosphatase (recAP) is effective and save, and to determine the most effective dose, in the treatment of patients with acute kidney injury caused by sepsis.
- Trial name
- STOP-AKI (NCT02182440)
- Testing
- recAP
- Where
- 58 sites in United States, Austria and 9 more
- Volunteers
- 301 people
- Sponsor
- AM-Pharma